Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?

被引:29
|
作者
Kulozik, Felix [1 ]
Hasslacher, Christoph [1 ]
机构
[1] Diabet Inst Heidelberg, Landhausstr 25, D-69115 Heidelberg, Germany
关键词
diabetic nephropathy; renal insufficiency; insulin requirement; human insulin; insulin analogues; insulin glargin; insulin detemir; insulin lispro; insulin aspart;
D O I
10.1177/2042018813501188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: In diabetic nephropathy the decline of renal function causes modifications of the insulin and carbohydrate metabolism resulting in changed insulin requirements. The aim of the present study was to identify potential differences in the requirements of human insulin and various insulin analogues in patients with type 1 diabetes mellitus and renal dysfunction. Methods: The insulin requirements of 346 patients with type 1 diabetes mellitus under everyday life circumstances were assessed in an observational study. Simultaneously, laboratory parameters were measured and the estimated glomerular filtration rate (eGFR) was calculated using the formula by Cockcroft-Gault. Medical history and concomitant medication were recorded. The insulin requirements of long-and short-acting insulin were tested for a relationship with the eGFR and laboratory parameters. Results: The dosage of long-acting human insulin did not show any relation to eGFR. In contrast, a strong positive relation between dosage and renal function was found for insulin glargine and insulin detemir. After classification according to renal function, the insulin dosage at eGFR less than 60 ml/min was 29.7% lower in glargine-treated and 27.3% lower in detemir-treated patients compared with eGFR greater than 90 ml/min. Considering the whole range of eGFR, short-acting human insulin did not show a relation with renal function. Only after classification according to renal function was a dose reduction found for human insulin at eGFR less than 60 ml/min. In contrast, requirements of insulin lispro were significantly related to eGFR over the whole range of eGFR. At eGFR less than 60 ml/min the insulin dosage was 32.6% lower than at eGFR greater than 90 ml/min. The requirements of insulin aspart did not show any association with the eGFR. Conclusions: Patients with type 1 diabetes mellitus show different insulin requirements according to the renal function depending on the applied insulin. This finding is essential for the adjustment of insulin therapy in patients with diabetic nephropathy to achieve balanced glycemic control. To determine the underlying mechanisms, further studies on the pharmacokinetics and pharmacodynamics of the different insulins in patients with diabetic nephropathy are needed.
引用
收藏
页码:113 / 121
页数:9
相关论文
共 50 条
  • [41] Human versus porcine insulin in patients with insulin-dependent diabetes mellitus:: Differences in sleep and the sleep EEG during near-normoglycemia
    Roth, C
    Landolt, HP
    Achermann, P
    Teuscher, A
    Borbély, AA
    SLEEP, 1998, 21 (01) : 92 - 100
  • [42] The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes
    Gallagher, A.
    Butler, T. J.
    Home, P. D.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (03) : 327 - 334
  • [43] Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes
    Esposito, Katherine
    Giugliano, Dario
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (02) : 209 - 221
  • [44] Evaluation of the pituitary function with insulin tolerance (hypoglycaemia) testing: Are there any differences using insulin lispro compared to regular insulin?
    Yuen, Kevin C. J.
    Amin, Rakesh
    Cook, Marie B.
    Rhoads, Sharon A.
    Cook, David M.
    HORMONE RESEARCH, 2008, 69 (04) : 233 - 239
  • [45] Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis
    Monami, M.
    Marchionni, N.
    Mannucci, E.
    DIABETES OBESITY & METABOLISM, 2009, 11 (04): : 372 - 378
  • [46] Comparative analysis of glycemic control effectiveness and microvascular complications in patients with type 1 diabetes mellitus, treated with genetically engineered human insulin or human insulin analogues: A 10-year retrospective observational study
    Shestakova, Marina V.
    Efremova, Natalia V.
    Bolotskaya, Lubov L.
    Sklyanik, Igor A.
    Philippov, Yury I.
    Dedov, Ivan I.
    DIABETES MELLITUS, 2016, 19 (05): : 388 - 396
  • [47] Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study
    Anna But
    Marie L. De Bruin
    Marloes T. Bazelier
    Vidar Hjellvik
    Morten Andersen
    Anssi Auvinen
    Jakob Starup-Linde
    Marjanka K. Schmidt
    Kari Furu
    Frank de Vries
    Øystein Karlstad
    Nils Ekström
    Jari Haukka
    Diabetologia, 2017, 60 : 1691 - 1703
  • [48] Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter]
    U. Grouven
    L. G. Hemkens
    R. Bender
    P. T. Sawicki
    Diabetologia, 2010, 53 : 209 - 211
  • [49] Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study
    But, Anna
    De Bruin, Marie L.
    Bazelier, Marloes T.
    Hjellvik, Vidar
    Andersen, Morten
    Auvinen, Anssi
    Starup-Linde, Jakob
    Schmidt, Marjanka K.
    Furu, Kari
    de Vries, Frank
    Karlstad, Oystein
    Ekstrom, Nils
    Haukka, Jari
    DIABETOLOGIA, 2017, 60 (09) : 1691 - 1703
  • [50] Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter]
    Grouven, U.
    Hemkens, L. G.
    Bender, R.
    Sawicki, P. T.
    DIABETOLOGIA, 2010, 53 (01) : 209 - 211